In this issue:
Molecular monitoring to guide AML treatment
SAKK 34/17: a modified ibrutinib + venetoclax schedule in relapsed/ refractory CLL
MORPHO: a post-hoc analysis of FLT3-ITD MRD & RFS
Watchful waiting vs. early rituximab monotherapy for asymptomatic, advanced stage, low tumour burden follicular lymphoma
GIMEMA LAL2317: front-line chemotherapy-blinatumomab in adult Ph- B-ALL
POLARIX: Pola-R-CHP vs. R-CHOP in DLBCL patients aged ≥60, ≥65, ≥70 and ≥75 years
Romi-GemOxD in relapsed/refractory aggressive lymphomas
RELEVANCE: prognostic value of LMR in high tumour burden follicular lymphoma
First-line rituximab, methotrexate, orelabrutinib in primary CNS lymphoma
Venetoclax + CALGB 10403 regimen in adults with newly diagnosed Ph- B-ALL
Please login below to download this issue (PDF)